Core Points - Wereldhave N.V. has proposed the appointment of Mr. Marcel Eggenkamp as Chief Financial Officer (CFO) and member of the Board of Management, pending approval at the Annual General Meeting of Shareholders on May 13, 2026 [1] - Marcel Eggenkamp has extensive international financial and real estate expertise, having served as CFO at Edge from 2019 to 2025 and at Redevco from 2011 to 2019, along with senior roles at KPMG, Ballast Nedam, and KPN Telecom [2] - The proposed appointment, subject to shareholder approval, will be effective for a four-year term [2]

Core Viewpoint - DNO ASA has secured offtake agreements for its North Sea oil production with Exxon Mobil and Shell, along with related financing facilities totaling up to USD 410 million, enhancing its growth potential in uncertain markets [1][2][3]. Group 1: Offtake Agreements - The agreement with ExxonMobil covers approximately half of DNO's North Sea oil output, with a two-year tenor and a revolving credit facility of up to USD 185 million [2]. - The agreement with Shell covers the remaining half of the output, featuring an initial one-year tenor and a prepayment facility with a European bank of up to USD 225 million [2]. Group 2: Financing Facilities - The offtake agreements with Exxon Mobil and Shell provide significant financing at attractive rates, facilitating growth opportunities for the company [3]. - Combined with a gas offtake agreement with ENGIE SA announced in July, DNO has established financing facilities totaling up to USD 910 million linked to its North Sea oil and gas production [3]. Group 3: Company Background - DNO ASA is a Norwegian oil and gas operator with operations in the Middle East, North Sea, and West Africa, founded in 1971 and listed on the Oslo Stock Exchange since 1981 [4]. - The company holds interests in various onshore and offshore licenses at different stages of exploration, development, and production across several regions, including the Kurdistan region of Iraq, Norway, the United Kingdom, Côte d'Ivoire, and Yemen [4].

Core Insights - The company has made significant investments to enhance guest experiences ahead of the winter season [2] - Demand for mountain holidays remains stable, with a slight decrease in booking volume compared to the previous year [7] Financial Performance - Net sales for the first quarter increased by SEK 24 million, or 11 percent, reaching SEK 236 million compared to SEK 212 million in the previous year [7] - Operating profit for the first quarter showed a slight improvement, increasing by SEK 4 million, or 1 percent, to SEK -478 million from SEK -482 million [7] - Cash flow from operating activities decreased by SEK 13 million to SEK 254 million, down from SEK 267 million [7] - Basic and diluted earnings per share improved by 4 percent, amounting to SEK -5.04 compared to SEK -5.26 [7] Dividend and Share Information - A dividend of SEK 3.00 per share was approved at the Annual General Meeting held in Sälen on 13 December [7] - Effective 2 January 2026, the company's class B share will be transferred to Nasdaq Stockholm's Large Cap segment [7] Company Overview - SkiStar AB operates mountain resorts in Sweden and Norway, focusing on creating memorable mountain experiences and sustainable destinations [5]

Core Insights - Molecular Partners AG is a clinical-stage biotech company focused on developing DARPin therapeutics, which are custom-built protein drugs aimed at addressing medical challenges that other drug modalities cannot effectively tackle [3] Group 1: Company Overview - Molecular Partners AG is pioneering the design and development of DARPin therapeutics, with a primary focus on oncology [3] - The company has various programs in different stages of pre-clinical and clinical development [3] - Founded in 2004, Molecular Partners has offices in Zurich, Switzerland, and Concord, Massachusetts, USA [3] Group 2: Upcoming Presentation - The CEO, Patrick Amstutz, will present the company's latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2025 [2] - The presentation will take place from 10:30 AM to 11:10 AM PT at the Westin St. Francis in San Francisco, CA [2] - A webcast of the presentation will be available on the Molecular Partners website [2]

Core Viewpoint - DMG Blockchain Solutions Inc. will release its audited financial results for the fourth quarter and full year 2025 on December 18, 2025, before the market opens [1] Financial Results Announcement - The company will host a conference call on December 18, 2025, at 4:30 PM ET to review its financial results and provide a corporate update [2] - Participants can register for the call via a provided link [2] Q&A Session - A live Q&A session will be available during the conference call, with management addressing pre-submitted questions [3] - Questions can be submitted via email until 2:00 PM ET on December 18, 2025 [3] Company Overview - DMG is a publicly traded, vertically integrated blockchain and data center technology company [4] - The company manages and develops digital solutions to monetize digital assets and AI compute ecosystems [4] - Systemic Trust Company, a subsidiary of DMG, plays a key role in its carbon-neutral Bitcoin ecosystem [4] - DMG offers a Bitcoin blockchain explorer called Blockseer Explorer, which is freely available [4]

Core Viewpoint - InnoCare Pharma has received approval for a Phase II/III clinical trial of its novel TYK2 inhibitor, soficitinib, aimed at treating chronic spontaneous urticaria (CSU), addressing significant unmet medical needs in the dermatology market [1][6]. Group 1: Drug Development - Soficitinib is a selective TYK2 inhibitor being developed for various T-cell related autoimmune disorders, including CSU, atopic dermatitis, and vitiligo [2]. - The drug works by blocking signaling pathways such as IL-4, IL-13, and IL-31, which are involved in mast cell activation and inflammation, thereby reducing symptoms like itch and wheals in CSU patients [3]. Group 2: Market Potential - Chronic spontaneous urticaria affects approximately 50 million patients globally, with the CSU treatment market projected to reach $3 billion by 2029 [5]. - The disease typically lasts two to five years, with some cases extending beyond five years, indicating a substantial need for long-term treatment options [4]. Group 3: Company Overview - InnoCare Pharma is focused on developing first-in-class and best-in-class drugs for cancer and autoimmune diseases, with a robust pipeline targeting ten major autoimmune diseases [6]. - The company operates in multiple locations, including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States, emphasizing its commitment to addressing unmet medical needs both in China and globally [6].

Core Viewpoint - Reeflex Solutions Inc. is unable to meet the December 29, 2025 filing deadline for its audited annual financial statements due to the complexity of transitioning to an IFRS-compliant public company following a reverse takeover and acquisition [1][2] Group 1: Filing Delays and Restatements - The company intends to restate its interim financial statements for the quarter ended May 31, 2025, to reflect results only from the acquisition date of May 15, 2025, in accordance with IFRS [2] - The timeline for completing the audit and preparing the annual filings has been extended due to first-time public company audit requirements [2][3] Group 2: Management Cease Trade Order (MCTO) - The company has applied for a Management Cease Trade Order (MCTO) from the Alberta Securities Commission, which would restrict the CEO and CFO from trading in the company's securities until the required filings are made [4] - The MCTO will not affect the general investing public's ability to trade in the company's common shares [4] Group 3: Operational Performance - The restatement of the Q3 filings is technical and does not impact the company's core operations, customer relationships, or business momentum [6] - The company continues to execute on manufacturing and international growth initiatives, including receiving $2.6 million in purchase orders for products in Saudi Arabia and a $3.4 million contract for product design and manufacturing [6]

Core Viewpoint - ThreeD Capital Inc. has disposed of 1,130,000 common shares of Avicanna Inc., reducing its ownership stake by over 2% on a partially diluted basis [1][4]. Group 1: Ownership Details - Prior to the dispositions, ThreeD and the Joint Actor owned 18,276,757 common shares, 1,441,250 common share purchase warrants, and 50,000 stock options, representing approximately 15.5% of all issued and outstanding common shares of Avicanna Inc. [2] - After the dispositions, ThreeD and the Joint Actor now own 17,146,757 common shares, maintaining approximately 14.6% of all issued and outstanding common shares of Avicanna Inc. [3] Group 2: Financial Transactions - The Subject Shares were disposed of for total consideration of $268,667, equating to approximately $0.238 per share [4]. Group 3: Company Profile - ThreeD Capital Inc. is a Canadian-based venture capital firm focused on opportunistic investments in junior resources and disruptive technologies sectors, aiming to invest in early-stage companies globally [5].

Core Viewpoint - Actelis Networks, Inc. has announced a public offering of 6,250,000 shares of common stock at a price of $0.80 per share, aiming to raise approximately $5 million in gross proceeds for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes warrants to purchase an additional 6,250,000 shares of common stock, with an exercise price of $0.80 per share, exercisable upon issuance and expiring five years thereafter [1]. - The closing of the offering is expected around December 19, 2025, pending customary closing conditions [1]. Group 2: Financial Information - The gross proceeds from the offering are anticipated to be $5 million before deducting placement agent fees and other expenses [2]. - H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering [2]. Group 3: Company Overview - Actelis Networks, Inc. specializes in hybrid fiber and cyber-hardened networking solutions for IoT applications across various sectors, including government, military, and telecom [5]. - The company’s offerings provide fiber-grade performance while maintaining the flexibility and cost-efficiency of hybrid fiber-copper networks [5]. - Actelis also emphasizes network security through its "Cyber Aware Networking" initiative, which includes AI-based cyber monitoring and protection for edge devices [5].

Core Viewpoint - Next Hydrogen Solutions Inc. has successfully closed a non-brokered private placement, raising approximately CAD$20.7 million through the issuance of 46,069,198 common shares at CAD$0.45 per share, marking a significant milestone in its transition to a commercially focused business delivering hydrogen electrolyzers [1][3][4] Financing and Shareholder Structure - The private placement was led by Smoothwater Capital Corporation, which has become the largest shareholder of Next Hydrogen, holding approximately 47.9% of the issued common shares, ensuring Canadian ownership and control [2][14] - A total of 42,323,590 common shares were issued for gross cash proceeds of approximately CAD$19.0 million, with no finder's fees or commissions paid [10][11] Business Strategy and Product Development - The net proceeds from the offering will be utilized to support the sales and production of the NH-150 electrolyzer and the development of the larger NH-500 system, aimed at unlocking substantial industrial opportunities [4][6] - Next Hydrogen's technology is designed for scalable deployment and direct integration with renewable energy sources, enhancing its competitive edge in the clean hydrogen market [5][6] Regulatory Environment and Market Position - The Canadian government is advancing supportive frameworks for clean hydrogen, including an investment tax credit of up to 40% for eligible projects, creating a favorable regulatory environment for the industry [8] - Next Hydrogen is positioned as a clean-technology champion in Canada, with the potential to support domestic energy security and provide globally competitive hydrogen solutions [6][7] Leadership Changes - Following the offering, Stephen Griggs from Smoothwater joined as Executive Chair of the Board, bringing extensive experience in operational discipline and governance [9][10] - Paul Currie, a seasoned business executive, also joined the Board, contributing significant global experience to guide the company in its transition to a commercial product-focused business [9][10] Technology and Market Applications - Next Hydrogen's pressurized alkaline electrolyzers are validated as commercially deployable solutions, delivering high performance and exceeding U.S. DOE targets for green hydrogen production [5][6] - The modular architecture of Next Hydrogen's systems supports deployment across various project sizes and applications, including industrial decarbonization and energy storage [6]